Format

Send to

Choose Destination
Curr Oncol Rep. 2017 Feb;19(2):11. doi: 10.1007/s11912-017-0569-6.

Current Management Strategy for Active Surveillance in Prostate Cancer.

Author information

1
Department of Urology, Yale School of Medicine, PO Box 208058, New Haven, CT, 06520-8058, USA.
2
Department of Urology, Yale School of Medicine, PO Box 208058, New Haven, CT, 06520-8058, USA. Preston.Sprenkle@yale.edu.

Abstract

PURPOSE OF REVIEW:

Active surveillance has been increasingly utilized as a strategy for the management of favorable-risk, localized prostate cancer. In this review, we describe contemporary management strategies of active surveillance, with a focus on traditional stratification schemes, new prognostic tools, and patient outcomes.

RECENT FINDINGS:

Patient selection, follow-up strategy, and indication for delayed intervention for active surveillance remain centered around PSA, digital rectal exam, and biopsy findings. Novel tools which include imaging, biomarkers, and genetic assays have been investigated as potential prognostic adjuncts; however, their role in active surveillance remains institutionally dependent. Although 30-50% of patients on active surveillance ultimately undergo delayed treatment, the vast majority will remain free of metastasis with a low risk of dying from prostate cancer. The optimal method for patient selection into active surveillance is unknown; however, cancer-specific mortality rates remain excellent. New prognostication tools are promising, and long-term prospective, randomized data regarding their use in active surveillance will be beneficial.

KEYWORDS:

Active surveillance; Biomarkers; Gene assay; Prostate cancer

PMID:
28220449
DOI:
10.1007/s11912-017-0569-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center